Lucid Diagnostics Inc (NASDAQ:LUCD)’s traded shares stood at 1.04 million during the last session, with the company’s beta value hitting 1.36. At the close of trading, the stock’s price was $1.50, to imply an increase of 5.26% or $0.08 in intraday trading. The LUCD share’s 52-week high remains $1.63, putting it -8.67% down since that peak but still an impressive 58.0% since price per share fell to its 52-week low of $0.63.
Analysts have given a consensus recommendation of Buy for Lucid Diagnostics Inc (LUCD), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 1 analyst(s) give LUCD a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.15.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
After registering a 5.26% upside in the last session, Lucid Diagnostics Inc (LUCD) has traded red over the past five days. The 5-day price performance for the stock is 0.67%, and 66.81% over 30 days. With these gigs, the year-to-date price performance is 83.22%.
The extremes give us $2.5 and $2.5 for target low and target high price respectively. As such, LUCD has been trading -66.67% off suggested target high and -66.67% from its likely low.
Lucid Diagnostics Inc (LUCD) estimates and forecasts
The rating firms project that company’s revenue will grow 88.04% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 1.42M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 1.61M.Earnings reports from the last fiscal year show that sales brought in 1.04M and 1M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 36.95% before jumping 61.32% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -110.66% for the past 5-year period. While 2025 is set for a 84.60% return in earnings, projections for the next 5 years are at 58.74% annually.
LUCD Dividends
Lucid Diagnostics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 0.56 million shares, or about 1.2461% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.46 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Lucid Diagnostics Inc (LUCD) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 366.92 shares. This is just over 0.62% of the total shares, with a market valuation of $0.55 million. Data from the same date shows that the other fund manager holds a little less at 193.99, or 0.33% of the shares, all valued at about 0.29 million.
